Clinical Trials- Carcinoid

A Phase 3, Randomized, Placebo-Controlled, Parallel-Group, Multicenter, Double- Blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in  Patients with Carcinoid Syndrome Refractory to Somatostatin Analog (SSA) Therapy(Lexicon LX1606.1-301-CS)  III  Gladys Pierce RN
 Nebraska Methodist Hospital,
Omaha NE







Nebraska Oncology Society
c/o Nebraska Medical Association
Sarah Dunbar
Executive Director
233 South 13th Street Suite 1200
Lincoln, NE 68508 (email)
402-474-4472 (phone)
402-474-2198 (fax)

Powered by Wild Apricot Membership Software